29.90

4.14% +1.19

Morphic Holding Inc (MORF)

Overview News Price History Option Chain Financials Why MORF Down? Discussions Forecast

Morphic Holding Inc stock is currently priced at $29.90, with a 24-hour trading volume of 309.87K. It has seen a +4.14% increased in the last 24 hours and a -5.71% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $28.66 pivot point. If it approaches the $30.30 resistance level, significant changes may occur.

Previous Close:

$28.71

Open:

$29.85

24h Volume:

309.87K

Market Cap:

$1.50B

Revenue:

$68.95M

Net Income/Loss:

$-161.25M

P/E Ratio:

-9.373

EPS:

-3.19

Net Cash Flow:

$-128.61M

1W Performance:

+6.52%

1M Performance:

-5.71%

6M Performance:

+32.48%

1Y Performance:

-41.59%

1D Range:

$29.07

$30.26

52W Range:

$19.34

$63.08

Morphic Holding Inc Stock (MORF) Company Profile

Name

Morphic Holding Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

781-996-0955

Address

35 Gatehouse Drive, A2, Waltham, MA

Employee

Twitter

@MorphicTx

Next Earnings Date

2024-05-31

Latest SEC Filings

MORF's Discussions on Twitter

Morphic Holding Inc Stock (MORF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-08-23	Initiated	Citigroup	Buy
Sep-25-23	Downgrade	BTIG Research	Buy → Neutral
Sep-25-23	Reiterated	Stifel	Hold
Aug-09-23	Downgrade	Stifel	Buy → Hold
Sep-07-22	Initiated	Stifel	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
Mar-31-22	Initiated	Canaccord Genuity	Buy
Feb-11-22	Initiated	BTIG Research	Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-26-20	Initiated	RBC Capital Mkts	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Wells Fargo	Outperform

View All

Morphic Holding Inc Stock (MORF) Latest News

What Makes Morphic (MORF) a New Buy Stock

Zacks Investment Research

Morphic to Participate in March Investor Conferences

GlobeNewswire Inc.

Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

Zacks Investment Research

Best Momentum Stocks to Buy for February 14th

Zacks Investment Research

New Strong Buy Stocks for February 14th

Zacks Investment Research

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet

Zacks Investment Research

Morphic Holding Inc Stock (MORF) Financials Data

Morphic Holding Inc (MORF) Revenue 2024

MORF reported a revenue (TTM) of $68.95 million for the quarter ending March 31, 2023, a +264.61% rise year-over-year.

Morphic Holding Inc (MORF) Net Income 2024

MORF net income (TTM) was -$161.25 million for the quarter ending March 31, 2024, a -153.18% decrease year-over-year.

Morphic Holding Inc (MORF) Cash Flow 2024

MORF recorded a free cash flow (TTM) of -$128.61 million for the quarter ending March 31, 2024, a -22.31% decrease year-over-year.

Morphic Holding Inc (MORF) Earnings per Share 2024

MORF earnings per share (TTM) was -$3.50 for the quarter ending March 31, 2024, a -113.41% decline year-over-year.

Morphic Holding Inc Stock (MORF) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Tipirneni Praveen P.	CEO	Jan 16 '24	Sale	27.49	13,923	382,753	42,013
Rogers Bruce	President	Jan 16 '24	Sale	27.49	6,314	173,576	142,036
SCHEGERIN MARC	CFO and COO	Jan 16 '24	Sale	27.49	6,041	166,071	37,460
Farrell Robert E Jr	SVP Finance and CAO	Jan 16 '24	Sale	27.49	5,089	139,900	34,992
DeVaul William	General Counsel and Secretary	Jan 16 '24	Sale	27.49	4,509	123,956	23,029
DeVaul William	General Counsel and Secretary	Jan 14 '24	Option Exercise	0.00	3,250	0	27,538
Farrell Robert E Jr	SVP Finance and CAO	Jan 14 '24	Option Exercise	0.00	3,470	0	40,081
Rogers Bruce	President	Jan 14 '24	Option Exercise	0.00	5,070	0	148,350
SCHEGERIN MARC	CFO and COO	Jan 14 '24	Option Exercise	0.00	4,690	0	43,501
Tipirneni Praveen P.	CEO	Jan 14 '24	Option Exercise	0.00	12,500	0	55,936

Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.